Tag: Clinical
-
NCCN Models How to Tailor Cancer Care for Different Regions During 2026 World Cancer Congress
National Cancer Control Plans can and should include regionally appropriate guidelines according to abstracts presented by the National Comprehensive Cancer Network during global event hosted by the Union of International Cancer Control.PLYMOUTH MEETING, Pa. and HONG KONG, Sept. 24, 2026 /PRNewswire…
-
Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent
FDA Clearance and CE Mark Complete Aptiva’s Antiphospholipid Syndrome Portfolio, Expanding Global Access to Comprehensive APS Testing SAN DIEGO, Sept. 23, 2026 /PRNewswire/ — Werfen today announced that its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin A (IgA) Reagent has received both U.S….
-
Merry Life Biomedical Advances Global Phase 2 Trial of TML-6, Exploring Cellular Protein Clearance in Early Alzheimer's Disease
Global study brings together nine Taiwan medical centers, seven Swedish sites, and four U.S. centers to evaluate an oral therapy focused on autolysosomal biologyTAIPEI, Sept. 22, 2026 /PRNewswire/ — Merry Life Biomedical today announced the advancement of TML-6, a Taiwan-developed investigational o…
-
PT Prodia Diacro Laboratories Receives Frost & Sullivan's 2026 Southeast Asian Contract Research Organization Customer Value Leadership Recognition for Customer-Centric Clinical Research Excellence
Prodia the CRO is recognized for its reliable, integrated clinical research ecosystem, customer-centric delivery model, and commitment to quality, innovation, and long-term sponsor value across Southeast Asia.SAN ANTONIO, Sept. 8, 2026 /PRNewswire/ — Frost & Sullivan is pleased to announce that…
-
NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury
Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life – Spinal Cord Research Foundation.SCHLIEREN, Switzerland, Sept. 2, 2026 /PRNewswire/ — NovaGo Therapeutics AG, a clini…
-
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ — Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company’s Phase 2b/3 clinical trial of its …
Latest News
About the Author
Publicize Your Brand
Through our news networks, we raise millions of users’ awareness. We are among the world’s most reputable news networks.
